Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Reshape Lifesciences Inc (RSLS)

Reshape Lifesciences Inc (RSLS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.3869 -0.0536 (-12.17%) 03/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.3939 +0.0070 (+1.81%) 18:57 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3867
Day High
0.4400
Open 0.4376
Previous Close 0.4405 0.4405
Volume 840,400 840,400
Avg Vol 574,575 574,575
Stochastic %K 1.20% 1.20%
Weighted Alpha -92.96 -92.96
5-Day Change -0.2771 (-41.73%) -0.2771 (-41.73%)
52-Week Range 0.3867 - 29.0000 0.3867 - 29.0000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,279
  • Shares Outstanding, K 3,305
  • Annual Sales, $ 8,680 K
  • Annual Income, $ -11,390 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.54
  • Price/Sales 0.02
  • Price/Cash Flow N/A
  • Price/Book 0.15
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -11.83
  • Most Recent Earnings $-3.11 on 11/14/24
  • Next Earnings Date 04/07/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1,182.51
  • Growth Rate Est. (year over year) +184.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3867 +0.05%
on 03/28/25
Period Open: 1.0300
1.2800 -69.77%
on 03/03/25
-0.6431 (-62.44%)
since 02/28/25
3-Month
0.3867 +0.05%
on 03/28/25
Period Open: 4.5500
5.1900 -92.55%
on 01/13/25
-4.1631 (-91.50%)
since 12/27/24
52-Week
0.3867 +0.05%
on 03/28/25
Period Open: 10.6952
29.0000 -98.67%
on 05/29/24
-10.3083 (-96.38%)
since 03/28/24

Most Recent Stories

More News
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS : 0.3869 (-12.17%)
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...

CVS : 67.14 (-0.67%)
EXAS : 43.66 (-2.96%)
ABBV : 205.29 (+1.27%)
RSLS : 0.3869 (-12.17%)
ALLR : 1.0400 (-0.95%)
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS : 0.3869 (-12.17%)
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS : 0.3869 (-12.17%)
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

RSLS : 0.3869 (-12.17%)
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS : 0.3869 (-12.17%)
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

RSLS : 0.3869 (-12.17%)
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS : 0.3869 (-12.17%)
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS : 0.3869 (-12.17%)
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary...

RSLS : 0.3869 (-12.17%)

Business Summary

ReShape Lifesciences Inc. provides weight-loss solutions. It offers an integrated portfolio of proven products and services which manage and treat obesity and metabolic disease. ReShape Lifesciences Inc., formerly known as Obalon Therapeutics, is based in SAN CLEMENTE, CA.

See More

Key Turning Points

3rd Resistance Point 0.4757
2nd Resistance Point 0.4578
1st Resistance Point 0.4224
Last Price 0.3869
1st Support Level 0.3691
2nd Support Level 0.3512
3rd Support Level 0.3158

See More

52-Week High 29.0000
Fibonacci 61.8% 18.0697
Fibonacci 50% 14.6933
Fibonacci 38.2% 11.3170
Last Price 0.3869
52-Week Low 0.3867

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies